The incidence of Ph-negative chronic myeloproliferative neoplasms in Belarus

  Introduction. Ph-negative myeloproliferative neoplasms (MPN) are chronic clonal disorders characterized by the proliferation of mature cells from one or more myeloid cell lines. These disorders include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The incidence of classical Ph-negative MPN varies significantly throughout the world. These differences may be due to geographical or population features, as well as due to differences in methods of diagnosis and recording.

   Aim: to determine incidence of Ph-negative MPN in Belarus.

   Materials and methods. Data on all cases of newly diagnosed Ph-negative MPNs (PV, ET and PMF) for 2014-2018 were collected from central regional medical institutions with a hematology specialization. Population epidemiological analysis of incidence was carried out by determining crude incidence rates per 100 000 population per year with distribution by gender
and age groups at diagnosis, age-standardized rates, as well as average annual percent change.

   Results. The overall annual standardized incidence rate of classical Ph-negative MPN in Belarus was 1.96 (1.86–2.07), PV — 0.93 (0.86–1.01), ET — 0.63 (0.57–0.70) and PMF — 0.40 (0.36–0.45) per 100 000 population per year, respectively. The overall crude incidence rate was 3.26 (3.10–3.43) per 100 000 population. The crude incidence rates increased steadily with the increase in age of patients with a peak value of 12.78 (10.97–14.81) in the age group of 70–74 years. No significant changes were revealed in the overall incidence of the MPN and for each of the studied diseases separately during the study period.

   Conclusion. For the first time the nationwide features of incidence of the Ph-negative MPN in Belarus were estimated, which made it possible to provide substantial information for public health management. The incidence of MPN in Belarus is generally comparable to the levels determined in the analysis of the populations of other countries.

1. Coltro G., Loscocco G.G., Vannucchi A.M. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. Int Rev Cell Mol Biol. 2021; 365: 1–69. DOI: 10.1016/bs.ircmb.2021.09.001.

2. Iland H.J., Laszlo J. Myeloproliferative Disorders: Polycythemia Vera, Essential Thrombocythemia, and Idiopathic Myelofi brosis/Agnogenic Myeloid Metaplasia. In: Hoogstraten B, Ed. Hematologic Malignancies UICC Current Treatment of Cancer. Berlin, Heidelberg: Springer; 1986. P 31–61. DOI: 10.1007/978-3-642-82734-1_3.

3. Melikyan A.L., Kovrigina A.M., Subortseva I.N., et al. National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofi brosis) (Edition 2020). Klinicheskaya onkogematologiya. 2021; 14(2): 262–98 (In Russian). DOI: 10.21320/2500-2139-2021-14-2-262-298.

4. Abdulkadyrov K.M., Shuvaev V.A., Martynkevich I.S. Myeloproliferative neoplasms. Saint Petersburg and Moscow: Litterra; 2016. 298 p. (In Russian).

5. Roaldsnes C., Holst R., Frederiksen H., et al. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. Eur J Haematol. 2017; 98(1): 85–93. DOI: 10.1111/ejh.12788.

6. Moulard O., Mehta J., Fryzek J., et al. Epidemiology of myelofi brosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014; 92(4): 289–97. DOI: 10.1111/ejh.12256.

7. Tefferi A., Vardiman J.W. Classifi cation and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008; 22(1): 14–22. DOI: 10.1038/sj.leu.2404955.

8. Arber D.A., Orazi A., Hasserjian R., et al. The 2016 revision to the World Health Organization classifi cation of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391–405. DOI: 10.1182/blood-2016-03-643544.

9. Titmarsh G.J., Duncombe A.S., Mcmullin M.F., et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014; 89(6): 581–7. DOI: 10.1002/ajh.23690.

10. Shuvaev V., Martynkevich I., Abdulkadyrova A., et al. Ph-Negative Chronic Myeloproliferative Neoplasms — Population Analysis, a Single Center 10-years’ Experience. Blood. 2014; 124(21): 5556. DOI: 10.1182/blood.V124.21.5556.5556.

11. Srour S.A., Devesa S.S., Morton L.M., et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–2012. Br J Haematol. 2016; 174(3): 382–96. DOI: 10.1111/bjh.14061.

12. Heppner J., Nguyen L.T., Guo M., et al. Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada. BMC Res Notes. 2019; 12(1): 286. DOI: 10.1186/s13104-019-4321-1.

13. Hultcrantz M., Ravn Landtblom A., Andréasson B., et al. Incidence of myeloproliferative neoplasms — trends by subgroup and age in a population-based study in Sweden. J Intern Med. 2020; 287(4): 448–54. DOI: 10.1111/joim.13019.

14. Baade P.D., Ross D.M., Anderson L.A., et al. Changing incidence of myeloproliferative neoplasms in Australia, 2003–2014. Am J Hematol. 2019; 94(4): E107–9. DOI: 10.1002/ajh.25407.

15. Vannucchi A.M., Barbui T., Cervantes F., et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(August): v85–99. DOI: 10.1093/annonc/mdv203.

16. The sex and age structure of the population of the Republic of Belarus as of January 1, 2015 and the average annual population for 2014: Stat. Bull. National. Stat. Com. Rep. Belarus. Minsk; 2015. 182 p. (In Russian).

17. The sex and age structure of the population of the Republic of Belarus as of January 1, 2019 and the average annual population for 2018: Stat. Bull. National. Stat. Com. Rep. Belarus. Minsk; 2019. 181 p. (In Russian).

18. Segi M. Cancer mortality for selected sites in 24 Countries (1950–1957). Sendai: Department of Public Health, Tohoku University School of Medicine; 1960.

19. Fay M.P., Tiwari R.C., Feuer E.J., et al. Estimating average annual percent change for disease rates without assuming constant change. Biometrics. 2006; 62(3): 847–54. DOI: 10.1111/j.1541-0420.2006.00528.x.

20. Spivak J.L. Myeloproliferative neoplasms. N Engl J Med. 2017; 376(22): 2168–81. DOI: 10.1056/NEJMra1406186.

21. Polyakov A.S., Noskov Y.A., Petrova O.R., et al. Diagnosis and treatment of Ph-negative myeloproliferative neoplasms in military medical organizations: guidelines. Saint Petersburg: Sergei Kirov Military Medical Academy; 2020. 84 p. (In Russian).

22. Nagurney J.T., Brown D.F.M., Sane S., et al. The accuracy and completeness of data collected by prospective and retrospective methods. Acad Emerg Med. 2005; 12(9): 884–95. DOI: 10.1197/j.aem.2005.04.021.

23. Kulikov S.M., Vinogradova O.Yu., Chelysheva E.Yu., et al. Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009–2012 population-based study. Ter Arkh. 2014; 86(7): 24–30 (In Russian).